Incidence rates of Guillain Barré (GBS), chronic fatigue/systemic exertion intolerance disease (CFS/SEID) and postural orthostatic tachycardia syndrome (POTS) prior to introduction of human papilloma virus (HPV) vaccination among adolescent girls in Finland, 2002-2012
- PMID: 28720463
- PMCID: PMC5883192
- DOI: 10.1016/j.pvr.2017.03.001
Incidence rates of Guillain Barré (GBS), chronic fatigue/systemic exertion intolerance disease (CFS/SEID) and postural orthostatic tachycardia syndrome (POTS) prior to introduction of human papilloma virus (HPV) vaccination among adolescent girls in Finland, 2002-2012
Abstract
Background: In Finland a vaccination programme against human papillomavirus (HPV) was introduced in November 2013 for girls aged 11-12 years with a catchup for girls 13-15 years. Allegations that HPV vaccine is causing Guillain Barré syndrome (GBS) and non-specific diagnostic entities, such as chronic fatigue syndrome/systemic exertion intolerance disease (CFS/SEID) and postural orthostatic tachycardia syndrome (POTS), continue to surface. We examined population register-based incidence rates of CFS/SEID, GBS and POTS to provide baseline data for future HPV vaccine safety evaluations.
Methods: First diagnosis of CFS/SEID, GBS and POTS in girls aged 11-15 years were obtained from the National Hospital Discharge Register during 2002-2012. We considered the following ICD-10 codes: G93.3 for CFS; G61.0 for GBS and G90.9, G90.8, G93.3, I49.8 for POTS. We calculated incidence rates per 100,000 person-years with 95% confidence intervals (CI).
Results: In total, 9 CFS/SEID, 19 GBS and 72 POTS cases were identified. The overall incidence rate was 0.53/100,000 (95% CI; 0.27-1.01) for CFS/SEID, 1.11 (95% CI; 0.71-1.74) for GBS and 4.21 (95%CI; 3.34-5.30) for POTS. Significant relative increase in annual incidence rate with a peak in 2012 was observed in CFS/SEID (33% (95% CI; 3.0-70.3: p=0.029) and POTS (16.5% (95% CI; 7.8-25.9: p<0.05), but not in GBS (5.4% (95% CI; -8.4-21.3: p=0.460).
Conclusions: Our findings provide baseline estimates of CFS/SEID, GBS and POTS incidences in Finland. However, rates based on register data should be interpreted with caution, especially for non-specific diagnostic entities for which internationally and even nationally agreed criteria are still being discussed. To assess the associations with HPV vaccine, methods using register linkage for cohort and self-controlled case series should be explored in addition to factors contributing to patients seeking care, treating physicians setting the diagnoses, and their preference of using of codes for these clinical entities.
Keywords: Chronic fatigue syndrome/Systemic exertion intolerance disease; Finland; Guillain Barré syndrome; Incidence rates; Papillomavirus vaccines; Postural orthostatic tachycardia syndrome; Vaccination adverse effects.
Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.
Figures





References
-
- World Health Organization Human papillomavirus vaccines: WHO position paper. Wkly. Epidemiol. Rec. 2014;43(89):465–492. - PubMed
-
- Paavonen J., Jenkins D., Bosch X., Naud P., Salmeron J., Wheeler C. Efficacy of a prophylactic adjuvanted L1 VLP vaccine against infection with HPV16 and 18 in young women: an interim analysis of a phase III double-blind, randomized controlled trial. Lancet. 2007;369:2161–2170. - PubMed
-
- Villa L., Perez G., Kjaer S., Lehtinen M., Paavonen J., Muñoz N. Efficacy of a quadrivalent HPV types 8/11/16/18) L1 virus-like particle vaccine in the prevention of cervical intraepithelial neoplasia grades 2/3 and adenocarcinoma in situ: a randomized controlled trial. N. Engl. J. Med. 2007;356:1915–1927. - PubMed
-
- National Institute for Health and Welfare (THL), Department of Vaccination and Immune Protection. HPV vaccination coverage in Finland; 2016 . (Accessed 11 April 2016).
-
- Finnish Medicines Agency (Fimea). Question E 9/2015 from the Nordic Council regarding adverse reactions to HPV-vaccine. Contribution from Finland to the question from the Nordic Council; 3 Nov 2015.
LinkOut - more resources
Full Text Sources
Other Literature Sources